Dose-Ranging Study of the Angiotensin II Receptor Antagonist Irbesartan (SR 47436/BMS-186295) on Blood Pressure and Neurohormonal Effects in Salt-Deplete Men

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 1, 1996, Pages 101-106

  McIntyre, M ^a   MacFadyen, R J ^a   Meredith, P A ^a   Brouard, R ^b   Reid, J L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b SANOFI   (France)

Author keywords

Angiotensin receptor antagonist; Angiotensin system blockade; Blood pressure reduction; Hormones; Irbesartan; Renin; SR47436 BMS186295

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; FUROSEMIDE; IRBESARTAN; RENIN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEPLETION;

ADULT; ANGIOTENSIN II; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIET, SODIUM-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; MALE; RECEPTORS, ANGIOTENSIN; RENIN; TETRAZOLES;

EID: 0029953317     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199607000-00016     Document Type: Article

References (22)

1. Peach MJ. Renin angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977;1:416-26.
2. Smith RD, Chiu AT, Wond PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin receptor antagonists. Annu Rev Pharmacol 1992;32:135-65.
3. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
4. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature of angiotensin receptors. Hypertension 1991;17:720-3.
5. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 1994;12:1333-8.
6. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterisation of SR 47436, a new nonpeptide ATI subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.
7. MacFadyen RJ, Elliott HL, Meredith PA, Reid JL. Haemodynamic and hormonal responses to low dose enalapril in salt depleted normotensive man. Br J Clin Pharmacol 1993; 35:299-301.
8. MacFadyen RJ, Jones CR, Doig JK, Birnbock H, Reid JL. Responses to an orally active renin inhibitor, remikiren (Ro 42-5892) following controlled salt depletion in man. J Cardiovasc Pharmacol 1995;25:347-53.
9. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954) in salt deplete normal man. J Cardiovasc Pharmacol 1993;21:732-8.
10. Derkx FHM, Boomsa F, Tan-Tijong HL, Schalekamp MADH. Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system. Clin Exp Hypertens 1972;2:575-92.
11. McIntyre M, MacFadyen RJ, Meredith PA, et al. Comparison of the oral angiotensin II receptor antagonist, UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt deplete man. J Cardiovasc Pharmacol 1995; 25:994-1000.
12. Brown JJ, Davies DL, Johnson NW, Lever AF, Robertson JIS. Renin relationships in congestive heart failure, treated and untreated. Am Heart J 1970;80:329-42.
13. Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JIS. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J 1983; 286:832-4.
14. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Robertson JIS, Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985;291:1309-12.
15. Lacourciere Y, Brunner HR, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
16. Semple PF, Thoren P, Lever AF. Vasovagal reactions to cardiovascular drugs: the first dose effect. J Hypertens 1988; 6:601-6.
17. Doig JK, MacFadyen RJ, Sweet CS, Reid JL. Haemodynamic and renal responses to losartan potassium in salt replete/deplete normal volunteers. J Cardiovasc Pharmacol 1995;25:511-7.
18. MacFadyen RJ, Lees KR, Reid JL. Responses to low dose perindoprilat infusion in salt deplete/salt replete normotensive volunteers. Br J Clin Pharmacol 1994;38:329-34.
19. Nussberger J, Keller I. Waeber B, Brunner HR. Angiotensin II measurement with high-affinity monoclonal antibodies. J Hypertens 1988;6(suppl 4):S424-35.
20. Schoenberger JA for Losartan Research Group. Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertension 1995;13(suppl 1):S43-7.
21. Shaw W, Keane W, Sica D, et al. Safety and antihypertensive effects of losartan (DuP753/MK954), a new angiotensin II receptor antagonist in patients with hypertension and renal disease [Abstract]. Clin Pharmacol Ther 1993;53:140.
22. Sweet CS, Rucinska EJ. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J 1994; 15:139-44.